Biotechnology 28 January 2026 - 9 March 2026

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
···

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3

Relmada Therapeutics will raise about $160 million in a private placement, priced at $4.75 a share, after reporting 12-month data showing a 76% complete response rate for NDV-01 in non-muscle invasive bladder cancer. The financing, expected to close by March 11, follows FDA feedback backing late-stage studies. NDV-01 showed no cases of disease progression or severe side effects among 25 patients at 12 months.
March 9, 2026
Tenaya Therapeutics Stock Jumps After $1.13 Billion Alnylam Heart-Disease Deal
···

Tenaya Therapeutics Stock Jumps After $1.13 Billion Alnylam Heart-Disease Deal

Tenaya Therapeutics and Alnylam Pharmaceuticals signed a cardiovascular drug target-discovery deal worth up to $1.13 billion, with Tenaya receiving up to $10 million upfront and research reimbursement. Tenaya shares jumped 40.9% to $0.8193 after the March 5 announcement. Alnylam will handle later-stage development and commercialization. Most of the payout depends on future milestones.
March 6, 2026
Arcus Biosciences stock pulls back after 17% pop; RCUS in focus after Leerink target hike
···

Arcus Biosciences stock pulls back after 17% pop; RCUS in focus after Leerink target hike

Arcus Biosciences shares fell 3.5% to $23.10 in early Tuesday trading, reversing part of Monday’s 17.5% surge. Leerink Partners raised its price target to $49 and maintained an “outperform” rating. Arcus recently reported updated kidney cancer data and ended 2025 with about $1 billion in cash. The company will present at the Leerink Global Healthcare Conference on March 9.
March 3, 2026
CRISPR Therapeutics stock price slides after takeover-chatter spike
···

CRISPR Therapeutics stock price slides after takeover-chatter spike

CRISPR Therapeutics shares dropped 4.7% to $58.82 in early Nasdaq trading Friday, erasing part of Thursday’s 11% surge tied to revived takeover speculation flagged by Betaville and The Fly. Investors await updates on Casgevy’s launch at early March conferences. Short interest stands near 26% of the float. Casgevy generated $54 million in Q4 revenue, with $116 million reported for 2025.
February 27, 2026
ImmunityBio stock price: IBRX ticks up in premarket after ANKTIVA sales surge and new approvals
···

ImmunityBio stock price: IBRX ticks up in premarket after ANKTIVA sales surge and new approvals

ImmunityBio shares rose about 1% premarket Tuesday after reporting 2025 ANKTIVA net product revenue of $113 million, up 700% year over year. The stock surged 13% Monday on heavy volume. ANKTIVA is now authorized for bladder cancer in 33 countries and recently received conditional approval for lung cancer in Saudi Arabia. The company ended 2025 with a net loss of $351.4 million and $242.8 million in cash.
February 24, 2026
Vir Biotechnology stock jumps 60%+ premarket on Astellas deal, upbeat VIR-5500 data
···

Vir Biotechnology stock jumps 60%+ premarket on Astellas deal, upbeat VIR-5500 data

Vir Biotechnology shares rose about 64% premarket after announcing a prostate cancer drug partnership with Astellas Pharma, bringing $335 million upfront and up to $1.37 billion in milestones. Updated Phase 1 data for VIR-5500 showed 82% of PSA-evaluable patients had at least a 50% PSA drop. Vir expects its cash to fund operations into Q2 2028. Fourth-quarter 2025 revenue reached $64.1 million, up from $12.4 million.
February 24, 2026
Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play
···

Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play

SELLAS Life Sciences shares rose 3.4% to $4.29 in premarket trading Monday after closing at $4.15 Friday. Investors are watching for the 80th event in the company’s Phase 3 AML study, which will trigger a final analysis. SELLAS reported $71.8 million in cash at year-end and recently raised $26.5 million from warrant exercises. Short interest stands at 41.33 million shares, about 24% of the float.
February 23, 2026
ImmunityBio stock steadies near a 52-week high as EU clears ANKTIVA; Accord rollout plan in focus
···

ImmunityBio stock steadies near a 52-week high as EU clears ANKTIVA; Accord rollout plan in focus

ImmunityBio shares traded near a 52-week high premarket after the European Commission granted conditional approval for ANKTIVA with BCG in bladder cancer. The company named Accord Healthcare and a Dublin unit for its European launch. Shares closed at $8.61 Thursday, up 41.9% Wednesday on heavy volume. Investors await updates at ASCO GU and feedback from the U.S. FDA.
February 20, 2026
ImmunityBio (IBRX) stock price spikes 42% on EU Anktiva nod — what traders watch next
···

ImmunityBio (IBRX) stock price spikes 42% on EU Anktiva nod — what traders watch next

ImmunityBio shares slipped 0.5% to $8.50 premarket Thursday after surging 41.9% on news the European Commission granted conditional marketing authorization for its bladder cancer therapy Anktiva plus BCG. The approval allows commercial rollout across 30 European countries for adults with BCG-unresponsive non-muscle invasive bladder cancer. Trading volume spiked to 78 million shares after the announcement.
February 19, 2026
Quince Therapeutics (QNCX) stock slides premarket as reverse-merger clock, Nasdaq risk hang over shares
···

Quince Therapeutics (QNCX) stock slides premarket as reverse-merger clock, Nasdaq risk hang over shares

Quince Therapeutics shares dropped about 9% to $0.18 in premarket trading Tuesday after the company warned it may need bankruptcy protection if it cannot secure a strategic deal. The biotech has no active programs following a failed trial and faces possible Nasdaq delisting. Investors await updates on financing or merger activity. U.S. markets reopen Tuesday after the Presidents Day holiday.
February 17, 2026
Vertex Pharmaceuticals stock jumps on 2026 outlook as Casgevy and Journavx come into focus
···

Vertex Pharmaceuticals stock jumps on 2026 outlook as Casgevy and Journavx come into focus

Vertex Pharmaceuticals shares rose 5.7% to $491.47 after hours Friday following a 2026 revenue forecast of up to $13.1 billion, matching Wall Street’s expectations. Fourth-quarter revenue reached $3.19 billion, with cystic fibrosis drugs Trikafta and Kaftrio accounting for $2.57 billion. Journavx prescriptions topped 550,000 through 2025. Casgevy sales more than tripled from the previous quarter.
February 13, 2026
U.S. senators move to police synthetic DNA sales as bioweapon fears sharpen
···

U.S. senators move to police synthetic DNA sales as bioweapon fears sharpen

Two U.S. senators introduced the Biosecurity Modernization and Innovation Act of 2026, requiring the Commerce Department to regulate synthetic DNA sales and screen orders for dangerous genetic sequences. The bill mandates audits, red-teaming, and penalties up to $750,000 for violations. It also proposes a federal list of “sequences of concern” and a NIST “governance sandbox” for oversight.
February 4, 2026
1 2